Cumberland reports positive cancer trial results for ifetroban drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
June 2, 2026 9:05 AM EDTPositive Results from Phase 2a Clinical Trial
Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors
Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)
Results support development of ifetroban as a candidate for metastasis prevention
NASHVILLE, Tenn., June 2, 2026... More
